"Retatrutide is among an emerging generation of weight loss drugs called GLP-3 agonists. While GLP-1 (glucagonlike peptide 1) agonist drugs such as semaglutide target a single hormone receptor that regulates hunger, GLP-3s target multiple receptors, including GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon receptor."
"Retatrutide is the first triple agonist drug to be tested in this way, and it was unclear whether it would be any more effective than currently approved drugs. While the data are still preliminary, they indicate that retatrutide has greater efficacy over a placebo for blood sugar and weight loss compared with previous trials of tirzepatide and semaglutide."
"Over the 40-week trial, participants saw a 1.7 to 2 percent decrease in A1C, a measure of average blood sugar levels, while on retatrutide. And those who took the highest trial dose of 12 milligrams lost an average of 36.6 pounds over the study period, according to Eli Lilly."
Retatrutide represents a new generation of weight-loss medications called GLP-3 agonists that target multiple hormone receptors—GLP-1, GIP, and glucagon—unlike earlier GLP-1 agonists that target only a single receptor. In a 40-week phase 3 clinical trial conducted by Eli Lilly, participants taking the highest dose of 12 milligrams experienced an average weight loss of 36.6 pounds and a 1.7 to 2 percent decrease in A1C, a measure of average blood sugar levels. Experts indicate retatrutide demonstrates greater efficacy compared to previously approved drugs like tirzepatide and semaglutide. The results represent a significant advancement as the first triple agonist drug tested in this manner, though full results remain unpublished and pending peer review.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]